Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allakos Inc ALLK

Healthcare Biotechnology
Allakos Inc. is a clinical-stage biotechnology company, which is engaged in the development of therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. The Company’s most advanced product candidate, AK006, is in a Phase I clinical trial. AK006 targets Siglec-6, an inhibitory receptor expressed selectively... see more

Recent & Breaking News (NDAQ:ALLK)

INVESTIGATION REMINDER: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Management of Allakos Inc.- ALLK

Business Wire June 10, 2022

INVESTIGATION ALERT: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Management of Allakos Inc.- ALLK

Business Wire June 9, 2022

Allakos Provides Business Update and Reports First Quarter 2022 Financial Results

GlobeNewswire May 6, 2022

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire March 1, 2022

Allakos to Host Investor Day on February 15

GlobeNewswire February 1, 2022

Allakos Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal Diseases

GlobeNewswire December 21, 2021

Allakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma

GlobeNewswire November 30, 2021

Allakos Provides Business Update and Reports Third Quarter 2021 Financial Results

GlobeNewswire November 8, 2021

Allakos Presents Data at ACG 2021 from Prospective Study Showing High Prevalence Rates of Eosinophilic Gastritis and/or Eosinophilic Duodenitis with Systematic Evaluation

GlobeNewswire October 25, 2021

Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the American College of Gastroenterology 2021 Annual Scientific Meeting

GlobeNewswire October 24, 2021

Allakos Provides Business Update and Reports Second Quarter 2021 Financial Results

GlobeNewswire August 9, 2021

Allakos Completes Patient Enrollment in Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodenitis and Phase 2/3 Eosinophilic Esophagitis Clinical Trials of Lirentelimab (AK002)

GlobeNewswire June 7, 2021

New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is Highly Underdiagnosed and may be a Common Cause of Moderate-to-Severe Gastrointestinal Symptoms

GlobeNewswire May 24, 2021

Allakos Reports First Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire May 10, 2021

Allakos Appoints Baird Radford as Chief Financial Officer

GlobeNewswire April 19, 2021

Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2021 DDW Annual Meeting

GlobeNewswire March 30, 2021

Allakos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

GlobeNewswire March 1, 2021

Allakos Appoints Natalie Holles to its Board of Directors

GlobeNewswire December 22, 2020

Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update

GlobeNewswire November 9, 2020

Allakos Announces Presentation from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2020 Annual Scientific Meeting

GlobeNewswire November 2, 2020